12d agoBarron'sBULLISH 67General
Archived explainer. For the current picture see today's NVS page.
Why Is NOVARTIS AG ADR (NVS) Stock Up Today?
By the Top Tier Newswire AI Desk · September 1, 2026 at 9:32 AM ET · reviewed against 15 wire stories
NOVARTIS AG ADR (NVS) is up +7.04% in the latest session. Our newswire has captured 15 stories on NVS across 8 sources in the last 36 hours, with AI sentiment reading mixed (avg 48/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why NVS stock is up today
Novartis AG ADR (NVS) surged 7.04% to $162.76 in the session, marking one of its largest intraday gains in recent months. The rally followed the release of positive Phase III trial results for its drug remibrutinib, which met primary endpoints in treating relapsing multiple sclerosis. The results, combined with a gap up of 4.4% at the open, signaled strong investor confidence in the company’s pipeline progress.
What Happened
Novartis announced the successful completion of two Phase III trials for remibrutinib, an oral BTK inhibitor, in treating relapsing multiple sclerosis. The drug significantly reduced relapse rates, meeting its primary goals. This development came alongside news that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved remibrutinib for chronic spontaneous urticaria in adults. Meanwhile, the company temporarily paused trials for its autoimmune CAR-T therapy, RAP-cabtagene autoleucel, following three patient deaths. Despite the pause, the positive trial data for remibrutinib overshadowed the setback, driving the stock higher.
What The Data Shows
The stock opened with a 4.4% gap up and reached an intraday high of $163.52 at 9:30 AM ET. Volume was 0.4 million shares, twice the 3-month average. Over the past 8 sessions, the stock had declined 2.4% from $156.24 to $152.49. On August 31, the stock printed one fresh 52-week high and six fresh 52-week lows. Retail traders on social media platforms highlighted the gap and the trial results, though no specific price targets were cited. Recent congressional trades show two purchases by Senator Alan Armstrong between March 30 and March 31, 2026.
What To Watch
The next key event for Novartis will be its quarterly earnings report, which is not scheduled within the next 30 days. Investors should monitor coverage breadth and any follow-up developments on the remibrutinib regulatory path, as well as updates on the paused CAR-T trials.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
NVS by the numbers
Last: $162.76Session: +7.04%7 sessions: +0.98%Coverage: 15 stories / 8 sourcesAI sentiment: 48/100 (mixed)Mkt cap: $290.7BP/E: 23.052w: $121.57 to $170.46
The headlines behind the move
12d agoMorningstarBULLISH 71Product/PR
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
The Swiss pharmaceutical company said two trials for relapsing multiple sclerosis met their primary goal by showing its drug, known as remibrutinib and marketed as Rhapsido for the skin condition chronic spontaneous urticaria, reduced relapse rates compared to a rival treatment.
12d agoBarron'sNEUTRAL 50General
Sandisk, Marvell, Robinhood, Novartis, Dell, and More Stocks That Explain Today’s Market
12d agoThe FlyBEARISH 32General
Novartis halts autoimmune CAR-T trials following three deaths, Reuters says
12d agoThe FlyBULLISH 67Product/PR
Novartis announces results from Phase III Remodel-1/-2 trials of remibrutinib
12d agoCNBCNEUTRAL 50General
Stocks making the biggest moves premarket: Nvidia, Robinhood, Novartis & more
These are the stocks posting the largest moves premarket.
12d agoSeeking AlphaNEUTRAL 50General
Biggest stock movers Tuesday: NVS, NIO, and more
Stock futures edged lower early Tuesday, putting Wall Street on track to open September on a lower note as investors weighed escalating Middle East tensions and
12d agoMorningstarBEARISH 34General
Dow Jones Top Company Headlines at 5 AM ET: Novartis Pauses Autoimmune Cell Therapy Studies After Deaths | Anthropic ...
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on NVS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier NVS move explainers: 2026-09-09 · 2026-09-08 · 2026-09-02 · 2026-09-01